Share Email Print
cover

Proceedings Paper

Studies of a novel photosensitizer palladium-bacteriopheophorbide (Tookad) for the treatment of prostate cancer
Author(s): Zheng Huang; Qun Chen; Pierre-Herve Brun; Brian C. Wilson; Avigdor Scherz; Yoram Salomon; David L. Luck; Jill Beckers; Fred W. Hetzel
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

In this study, photodynamic therapy (PDT) mediated with a novel, second generation photosensitizer Tookad (palladium-bacteriopheophorbide, WST09, STEBA Biotech, France), is investigated as an alternative modality in the treatment of prostate cancer. In vivo normal canine prostate and spontaneous advanced prostate cancer are used as the animal model. PDT was performed by irradiating the surgically exposed prostates with a diode laser (763 nm, 150 mW/cm) to activate the i.v. infused photosensitizer. The effects of drug concentration, drug-light interval, and light fluence rate on the PDT efficacy were studied. The prostates and adjacent tissues (bladder and underlying colon) were harvested and subjected to histopathological examination. During the one-week to 3-month period post PDT treatment, the dogs recovered well with little or no urethral complications. Prostatic urethra and prostate adjacent tissues (bladder and underlying colon) were well preserved. Light irradiation delivered during drug infusion or within 15 min post drug infusion induced the similar extend of damages. PDT induced prostate lesions in both normal and cancerous prostate were characterized by marked hemorrhagic necrosis and atrophy. Maximum lesion size of over 3 cm in dimension could be achieved with a single 1-cm interstitial treatment, suggesting the therapy is very effective in ablating cancerous prostatic tissue. In conclusion, the second generation photosensitizer Tookad mediated PDT may provide an effective alternative to treat prostate cancer.

Paper Details

Date Published: 13 June 2003
PDF: 11 pages
Proc. SPIE 4952, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XII, (13 June 2003); doi: 10.1117/12.474097
Show Author Affiliations
Zheng Huang, HealthONE Alliance (United States)
Qun Chen, HealthONE Alliance (United States)
Pierre-Herve Brun, STEBA Biotech (France)
Brian C. Wilson, Ontario Cancer Institute/Univ. Health Network (Canada)
Avigdor Scherz, Weizmann Institute of Science (Israel)
Yoram Salomon, Weizmann Institute of Science (Israel)
David L. Luck, HealthONE Alliance (United States)
Jill Beckers, HealthONE Alliance (United States)
Fred W. Hetzel, HealthONE Alliance (United States)


Published in SPIE Proceedings Vol. 4952:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XII
David Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top